ClinicalTrials.gg

Program

lead PB-212

Also written as “[212Pb]Pb-PSV359”, “[212Pb]Pb-MP0712” and “[212Pb]VMT-α-NET”.

Its studies are mostly in Stomach Neoplasms · Small Cell Lung Carcinoma · Gastro-enteropancreatic neuroendocrine tumor, led by 2 companies.

Furthest: phase 2, since Nov 15, 20223 company-led studies, 3 open or runningNext primary completion: Jan 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Perspective Therapeutics22 open or runningphase 2since Nov 15, 2022Nov 15, 2022Jan 31, 2028phase 2 · NCT06710756
Molecular Partners11 open or runningphase 2since Nov 10, 2025Nov 10, 2025Sep 2028phase 2 · NCT07278479

Also a collaborator on its studies: orano-med-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 15, 2022First study: phase 2 study in Gastro-enteropancreatic neuroendocrine tumorNew to Perspective TherapeuticsPerspective Therapeutics · NCT05636618 · 300 planned · United States
  2. Nov 25, 2024Phase 2 study in Stomach NeoplasmsPerspective Therapeutics · NCT06710756 · 112 planned · United States
  3. Nov 10, 2025Molecular Partners's first study: phase 2 study in Small Cell Lung CarcinomaNew to Molecular PartnersMolecular Partners · NCT07278479 · 138 planned · United States

Ahead

  1. Jan 31, 2028Primary completion: phase 2 study in Stomach NeoplasmsPerspective Therapeutics · NCT06710756
  2. Sep 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaMolecular Partners · NCT07278479
  3. Nov 26, 2029Primary completion: phase 2 study in Gastro-enteropancreatic neuroendocrine tumorPerspective Therapeutics · NCT05636618

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07278479Small Cell Lung Carcinoma · United States2RecruitingMolecular PartnersSep 2028138
NCT06710756Stomach Neoplasms · United States2RecruitingPerspective TherapeuticsJan 31, 2028112
NCT05636618Gastro-enteropancreatic neuroendocrine tumor · United States2RecruitingPerspective TherapeuticsNov 26, 2029300

How it is read

Names in the registry

  • “[212Pb]Pb-PSV359”, 1 entry
  • “[212Pb]Pb-MP0712”, 1 entry
  • “[212Pb]VMT-α-NET”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.